Figure 1. a and b, in vitro Cdk5 assay with rosiglitazone, ML244 or SR1824 with PPARγ or Rb substrates.

Figure 1

a and b, in vitro Cdk5 assay with rosiglitazone, ML244 or SR1824 with PPARγ or Rb substrates. c, TNF-α-induced phosphorylation of PPARγ in differentiated PPARγ KO MEFs expressing PPARγWT treated with rosiglitazone, ML244 or SR1824. These data are available as PubChem AID 504938.

From: Potent Anti-Diabetic Actions of a Novel Non-Agonist PPARγ Ligand that Blocks Cdk5-Mediated Phosphorylation

Cover of Probe Reports from the NIH Molecular Libraries Program
Probe Reports from the NIH Molecular Libraries Program [Internet].

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.